Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 20/20 | 0.69 |
| ▸ | CRBN | Q96SW2 | 20/20 | 0.69 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | IL1B | P01584 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21427006 | 0.93 | DDB1 (0.60) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL19953931 | 0.81 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL16209843 | 0.81 | DDB1 (1.00) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL13881408 | 0.80 | DDB1 (0.71) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL18843829 | 0.80 | DDB1 (0.67) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL21427003 | 0.80 | CRBN (0.62) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3657756 | 0.80 | DDB1 (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3653462 | 0.80 | CRBN (0.74) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL3655358 | 0.79 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26192246 | 0.79 | CRBN (0.77) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584133-B2 | Thienopyrimidinone compounds | BIOTHERYX, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190322682-A1 | THIENOPYRIMIDINONE COMPOUNDS | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-20190322682-A1 | THIENOPYRIMIDINONE COMPOUNDS | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| WO-2019191451-A1 | THIENOPYRIMIDINONE COMPOUNDS | BIOTHERYX, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322682-A1 | THIENOPYRIMIDINONE COMPOUNDS | MAVS, BRCA1, HSPE1 | DDB1 22/4885CRBN 216/4885IKZF3 1668/4885 |
| US-10584133-B2 | Thienopyrimidinone compounds | MAVS, BRCA1, HSPE1 | DDB1 22/4885CRBN 216/4885IKZF3 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.